The proinflammatory and hypercoagulable state of diabetes mellitus

Reviews in Cardiovascular Medicine

Volumn 6, Issue 2, 2005, Pages 84-97

  Aras, Rohit ^a   Sowers, James R ^b   Arora, Rohit ^a  

^a Robert Wood Johnson University   (United States)

^b University of Missouri   (United States)

Author keywords

Cardiovascular disease; Diabetes; Hypercoagulability; Insulin resistance syndrome

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ACUTE PHASE PROTEIN; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CD40 ANTIGEN; CD40 LIGAND; CELL ADHESION MOLECULE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLUCOCORTICOID; GLUCOSE; GROWTH FACTOR; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LYMPHOTOXIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; ROSIGLITAZONE; SALICYLIC ACID; SULFONYLUREA; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; ENDOTHELIUM LESION; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; LOW DRUG DOSE; MORTALITY; NEUROLOGIC DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PREDICTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; RISK REDUCTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD COAGULATION DISORDERS; CARDIOVASCULAR DISEASES; CORONARY ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 21044446270     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Haffner SM, Mykkanen L, Festa A, et al. Insulin-resistant pre-diabetic subjects have more atherogenic risk factors than insulin-sensitive pre-diabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975-980.
2. Kendall DM, Sobel BE, Coulston AM, et al. The insulin resistance syndrome and coronary artery disease. The Partners Against Insulin Resistance Advisory Panel [Perspective]. Coron Artery Dis. 2003;14:335-348.
3. Hsueh WA. Introduction: new insight into understanding the relation of type 2 diabetes mellitus, insulin resistance, and cardiovascular disease. Am J Cardiol. 2003;92:1J-2J.
4. Tracy RP. Thrombin, inflammation, and cardiovascular disease: an epidemiologic perspective. Chest. 2003;124(3 suppl):49S-57S.
5. Ritchie DG, Levy BA, Adams MA, et al. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway. Proc Natl Acad Sci. 1982;79:1530-1534.
6. Klein BE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care. 2002;25:1790-1794.
7. Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med. 2004;116(suppl 1):11-22.
8. Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care. 1998;21:69-75.
9. McGill HC, McMahan CA, Malcom GT, et al. Relation of glycohemoglobin and adiposity to atherosclerosis in youth. Arterioscler Thromb Vasc Biol. 1995;15:431-440.
10. Bolk J, van der Ploeg T, Cornel JH, et al. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol. 2001;79:207-214.
11. Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation. 1999;99:2626-2632.
12. McGill HC, McMahan CA, Herderick EE, et al. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 2002;105:2712-2718.
13. Haffner SM, Stern MP, Hazuda HF, et al. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-2898.
14. Haffner SJ. Hyperglycemia as a cardiovascular risk factor. Am J Med. 2003;115(suppl 8A): 6S-11S.
15. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42-47.
16. Lyon CJ. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology. 2003;144: 2195-2200.
17. Baumann H, Gauldie J. The acute phase response. Immunol Today. 1994;15:74-80.
18. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003;24:278-301.
19. Volpato S, Guralnik J, Ferrucci L, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women - The Women's Health and Aging Study. Circulation. 2001;103:947-953.
20. McMillan DE. Increased levels of acute-phase proteins in diabetes. Metabolism. 1989;38: 1042-1046.
21. van Exel E, Gussekloo J, de Craen AJ, et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes. 2002;51:1088-1092.
22. Huber SA, Sakkinen P, Conze D, et al. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999;19: 2364-2367.
23. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286:327-334.
24. Rosano GM, Gebara O, Mercuro G, et al. Increased C-reactive protein levels in women at increased cardiovascular risk predict one-year events only when associated with increased interleukin-6 levels. J Am Coll Cardiol. 2002;39: 881-885.
25. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Science. 1996;271:665-668.
26. Siwik DA, Chang DLF, Colucci WS. Interleukin-1β and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in vitro. Circ Res. 2000; 86:1259-1265.
27. Barath P, Fishbein MC, Cao J, et al. Detection and localization of TNF in human atheroma. Am J Cardiol. 1989;21:1241-1251.
28. Lopes-Virella M, Virella G. Cytokines, modified lipoproteins, and arteriosclerosis in diabetes. Diabetes. 1996;45(suppl 3):S40-S44.
29. Dandona P. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol. 2002;90:27G-33G.
30. Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med. 2004;116(suppl 1):9-16.
31. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
32. Kushner I, Sehgal AR. Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk? Arch Intern Med. 2002; 162:867-869.
33. Mosca L. C-reactive protein - to screen or not to screen? [editorial]. N Engl J Med. 2002;347: 1615-1617.
34. Rackley CE. New clinical markers predictive of cardiovascular disease: the role of inflammatory mediators. Cardiol Rev. 2004;12:151-157.
35. Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs. 1997;54(suppl 3): 32-40.
36. Tracy RP, Arnold AM, Ettinger W, et al. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly: results from the cardiovascular health study. Arterioscler Thromb Vasc Biol. 1999;19:1776-1783.
37. Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J. 1987;114: 413-419.
38. Cushman M, Psaty BM, Macy E, et al. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vasc Biol. 1996;16:1163-1169.
39. Tracy RP. Epidemiological evidence for inflammation in cardiovascular disease. Thromb Haemost. 1999;82:826-831.
40. Szmitko PE, Wang C, Weisel RD, et al. New markers of inflammation and endothelial cell activation: part I. Circulation. 2003;108: 1917-1923.
41. Varo N, Vicent D, Libby P, et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation. 2003;107:2664-2669.
42. Nikolaidis LA, Levine TB. Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure? Cardiol Rev. 2004;12:158-170.
43. Rieusset J, Andreelli F, Auboeuf D, et al. Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-gamma in human adipocytes. Diabetes. 1999;48: 699-705.
44. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746-26749.
45. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun. 1996;221:286-289.
46. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002;87:2764-2769.
47. Sakkinen P, Wahl P, Cushman M, et al. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol. 2000;152:897-907.
48. Meigs JB, Mittleman MA, Nathan DM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 2000;283:221-228.
49. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001;15:44-54.
50. Massberg S, Enders G, Leiderer R, et al. Platelet-endothelial cell interactions during ischemia/reperfusion: the role of P-selectin. Blood. 1998;92:507-512.
51. Mannaioni PF, DiBello MG, Masini E. Platelets and inflammation: role of platelet-derived growth factor, adhesion molecules and histamine. Inflamm Res. 1997;46:4-18.
52. Tschoepe D, Roesen P, Kaufmann L, et al. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest. 1990;20:166-170.
53. Tschoepe D, Driesch E, Schwippert B, et al. Exposure of adhesion molecules on activated platelets in patients with newly diagnosed IDDM is not normalized by near-normoglycemia. Diabetes. 1995;44:890-894.
54. McDonagh PF, Hokama JY, Gale SC, et al. Chronic expression of platelet adhesion proteins is associated with severe ischemic heart disease in type 2 diabetic patients: Chronic platelet activation in diabetic heart patients. J Diabetes Complications. 2003;17(5):269-278.
55. Meher-Homji NJ, Thilaganathan B, Nikolaides KH. Fetal platelet size and glycoprotein IB and IIIa expression in diabetic pregnancies. Br J Obstet Gynaecol. 1994;101:626-627.
56. Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation. 2003;108:420-425.
57. Sobel BE, Woodcock-Mitchell J, Schneider DJ, et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with non-diabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation. 1998;97:2213-2221.
58. Fonseca V, Desouza C, Asnani S, et al. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev. 2004;25:153-175.
59. Kawano H, Motoyama T, Hirashima O, et al. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol. 1999;34:146-154.
60. Beckman JA, Creager MA, Libby P, et al. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581.
61. Quehenberger P, Bierhaus A, Fasching P, et al. Endothelin 1 transcription is controlled by nuclear factor-κB in AGE-stimulated cultured endothelial cells. Diabetes. 2000;49:1561-1570.
62. Fonseca VA. Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease. Am J Cardiol. 2003;92:50J-60J.
63. Lehmann ED, Riley WA, Clarkson P, et al. Non-invasive assessment of cardiovascular disease in diabetes mellitus. Lancet. 1997;350(suppl 1): S114-S119.
64. Riley WA, Freedman DS, Higgs NA, et al. Decreased arterial elasticity associated with cardiovascular disease risk factors in the young. Bogalusa Heart Study. Arteriosclerosis. 1986;6: 378-386.
65. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
66. Pyorala M, Miettinen H, Laakso M, et al. Plasma insulin and all-cause, cardiovascular, and non-cardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care. 2000;23:1097-1102.
67. Cermak J, Key NS, Bach RR, et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82:513-520.
68. Strukova SM. Thrombin as a regulator of inflammation and reparative processes in tissues. Biochemistry (Mosc). 2001; 66:8-18.
69. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markets of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
70. Freed M, Fuell D, Menci L, et al. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes. Diabetologia. 2000;43(suppl 1):A267.
71. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83: 1818-1820.
72. McFarlane SI, Sowers JR. Aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease. J Clin Endocrinol Metab. 2003;88:516-523.
73. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999; 353:611-616.
74. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65.
75. Adler AI, Neil HA, Manley SE, et al. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). Am Heart J. 1999;138:S353-S359.
76. Furnary AP, Zerr KJ, Grunkemeier GL, et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 1999;67: 352-360, discussion 360-362.
77. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345:1359-1367.
78. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science. 2001;293:1673-1677.
79. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest. 2002;109:1321-1326.
80. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90: 625-628.
81. Sobel B, Frye R, Detre K. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2003;107: 636-642.
82. Frye R. Optimal care of patients with type 2 diabetes mellitus and coronary artery disease. Am J Med. 2003;115(suppl 1):93-98.
83. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med. 2002;19:527-534.